Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
Feature|Articles|July 14, 2026
Rethinking Longevity: Ingredients Built for Healthspan, Not Hype
Author(s)Shaheen Majeed, Sabinsa
Listen
0:00 / 0:00
Shaheen Majeed, Global CEO and Managing Director of Sabinsa, shares how the longevity category is positioned to close the gap between consumer expectations and product performance. Drawing on decades of ingredient science, Majeed outlines the biological targets, formulation strategies, and communication approaches that separate credible longevity products from hype-driven ones. With these insights, formulators and brand managers can create a roadmap for building trust and products that last.
Advertisement
Learn More About:
- The biological targets—oxidative stress, mitochondrial support, and the gut-immune axis—that matter most in longevity formulation today
- How bioavailability and ingredient layering strategies can bridge the gap between clinical research and real-world product performance
- How brands can communicate longevity benefits within regulatory guidelines while still building emotional trust with consumers
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
2
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
3
Thirty Years of GCP: The Evolution From Study Execution to Evidence Generation
4
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
5